Analysis examines what a meta-analysis of psychedelics versus antidepressants shows
An analysis by Dilara Oexemann for the OPEN Foundation examines a meta-analysis published in JAMA Psychiatry in March 2026 by Williams.
An analysis by Dilara Oexemann for the OPEN Foundation examines a meta-analysis published in JAMA Psychiatry in March 2026 by Williams.
OPEN Foundation analyses a May 8, 2026 ruling by the Amsterdam Healthcare Disciplinary Board.
OPEN Foundation has published its perspective on a 8 May 2026 ruling by the Regional Disciplinary Tribunal for Health Care in Amsterdam.
The Advisory Council on the Misuse of Drugs has advised the UK government that ketamine should remain a class B controlled substance, after the government asked it in January 2025 to review the prevalence and harms of ketamine misuse.
The Advisory Council on the Misuse of Drugs has published an updated review of the use and harms of ketamine, following a commission from the then Minister for Policing, Fire and Crime Prevention in January 2025. The report reviews prevalence and harms of ketamine and its analogues in the UK, describes legitimate uses including treatment and research, covers emerging health harms such as hepatobiliary toxicity, and describes supply and trafficking.
Why it matters: The review was commissioned to advise on ketamine's classification, so its findings on prevalence, hepatobiliary toxicity and supply could shape how the UK schedules the drug and its analogues.
The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.